Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

Earnings release - Q2 2026

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 14:20:12 2026-06-04 EDT			5-day change	1st Jan Change
0.4786 ^USD	+2.72%		0.00%	-11.71%

06-05	Senzime Launches Tetraanalytics Data Analytics Platform and Showcases Expanded Tetragraph Capabilities At Euroanaesthesia 2026	CI
06-03	Senzime secures new agreement with U.S. children's hospital	FW

Market Cap	693M 72.37M 63.1M 58.44M 54.71M 103M 6.83B 103M 269M 3.36B 272M 266M 11.67B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	693M 72.37M 63.1M 58.44M 54.71M 103M 6.83B 103M 269M 3.36B 272M 266M 11.67B	EV / Sales 2026 *	4.54x	EV / Sales 2027 *	2.98x
Free-Float	40.74%	Yield 2026 *	-	Yield 2027 *	-

06-05	Senzime Launches Tetraanalytics Data Analytics Platform and Showcases Expanded Tetragraph Capabilities At Euroanaesthesia 2026	CI
06-03	Senzime secures new agreement with U.S. children's hospital	FW
06-01	Senzime launches more sustainable EMG sensor	FW
05-27	Senzime gets additional FDA class II 510(k) clearance for Tetragraph system	RE
05-27	Senzime Secures Additional US FDA Clearance for TetraGraph Monitoring System	MT
05-27	Senzime receives FDA clearance for expanded Tetragraph system	FW
05-27	Senzime receives FDA 510(k) clearance for expanded Tetragraph system functionality	FW
05-27	Senzime Obtains FDA 510(k) Clearance For Enhanced TetraGraph System	CI
05-19	Senzime AB Elects Wolfgang Reim as Members of the Board of Directors	CI
04-29	Senzime bolsters US expansion with new Head of Sales	FW
04-24	Senzime's TetraGraph System Joins Catalogs of Three US Group Purchasing Organizations	MT
04-24	Senzime's TetraGraph system contracted on three GPO agreements in U.S.	RE
04-24	Senzime's TetraGraph system included in three U.S. procurement agreements	FW

25-09-04	Redeye Initiates Coverage of Senzime with a Target Value of SEK 12	FW
25-06-03	DNB Carnegie believes that Senzime's targeted issue is sufficient to achieve positive free cash flow.	FW
24-05-13	Senzime's order intake supports long-term growth case - Penser	FW
24-02-19	Strong growth expected from Senzime also in 2024 - Penser	FW
23-10-27	Penser reiterates motivated value for Senzime	FW

Senzime AB Stock OTC Markets

Stocks

SNZZF

SE0002478776

Medical Equipment, Supplies & Distribution

Valuation: Senzime AB

Chart: Senzime AB

Latest news : Senzime AB

Last Transcript: Senzime AB

Analysts' recommendations: Senzime AB

Press Releases: Senzime AB

Quotes and Performance

Course Extremes

Managers and Directors: Senzime AB

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

06-05	Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026	AQ
06-03	Senzime strengthens position in pediatric anesthesia by securing another hospital contract and highlighting positive outcome data	AQ
06-01	Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor	AQ
05-27	From science to practice: Senzime obtains FDA 510(k) clearance for enhanced TetraGraph system	AQ
05-19	BULLETIN FROM ANNUAL GENERAL MEETING IN SENZIME AB (PUBL)	AQ

1 day	+2.72%
Current month	+0.29%
1 month	+0.29%
3 months	-4.03%
6 months	+6.36%
Current year	-11.71%

1 month	0.47	0.5
Current year	0.47	0.62
1 year	0.45	0.74
3 years	0.25	0.96
5 years	0.25	3
10 years	0.25	3

Manager	Title	Age	Since
Philip Axel Wilhelm Siberg CEO	Chief Executive Officer	53	2023-05-02
Slavoljub Grujicic DFI	Director of Finance/CFO	56	2021-12-31
Fredrik Norrby CTO	Chief Tech/Sci/R&D Officer	50	2022-12-31

Director	Title	Age	Since
Lars Adam Holger Dahlberg CHM	Chairman	53	2023-05-02
Sorin Brull BRD	Director/Board Member	70	2015-12-31
Eva Walde BRD	Director/Board Member	63	2020-03-04

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SENZIME AB	+2.72%	0.00%	-	-	72.55M
ABBOTT LABORATORIES	-0.10%	+0.26%	-33.23%	-16.75%	154B
MEDTRONIC PLC	+1.54%	-1.07%	-7.45%	-11.00%	102B
HOYA CORPORATION	-4.45%	+3.12%	+59.84%	+56.09%	59.25B
CENCORA, INC.	-1.90%	-3.49%	-8.40%	+48.53%	52.89B
BECTON, DICKINSON AND COMPANY	+1.67%	-1.55%	-14.60%	-44.33%	39.67B
MEDLINE INC.	-1.32%	-1.83%	-	-	30.39B
DEXCOM, INC.	+1.74%	-3.85%	-10.54%	-44.30%	27.96B
WEST PHARMACEUTICAL SERVICES, INC.	+1.35%	-0.26%	+50.47%	-9.42%	23.17B
TERUMO CORPORATION	-1.53%	+1.14%	-15.03%	-5.42%	20.7B
Average	-0.03%	-0.55%	+2.63%	-3.32%	56.65B
Weighted average by Cap.	-0.29%	-0.33%	-5.82%	-2.37%

	2026 *	2027 *
Net sales	153M 15.94M 13.9M 12.87M 12.05M 22.6M 1.5B 22.74M 59.18M 740M 59.83M 58.55M 2.57B	232M 24.25M 21.14M 19.58M 18.33M 34.38M 2.29B 34.59M 90.03M 1.13B 91.02M 89.07M 3.91B
Net income	-65.3M -6.82M -5.94M -5.5M -5.15M -9.66M -643M -9.72M -25.31M -317M -25.59M -25.04M -1.1B	-26.3M -2.75M -2.39M -2.22M -2.08M -3.89M -259M -3.92M -10.19M -128M -10.31M -10.08M -443M
Net Debt	-	-